Placebo matching mepolizumab
Phase 3
GSKPlacebo matching mepolizumab is one of 3 therapeutic programs targeting Eosinophilic Granulomatosis With Polyangiitis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
3 competitors in Eosinophilic Granulomatosis With Polyangiitis
#DrugCompanyPhaseTrials
1EXDENSUR
GGlaxo Dba Glaxosmithkline
Phase 3
Nucala
GGlaxo Dba Glaxosmithkline
Phase 3
Placebo matching mepolizumab
GSKPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Eosinophilic Granulomatosis With Polyangiitis1 trial
Sources
References
- [1]
- [2]
- [3]